TMO
Bearish signalScored 2026-09-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Thermo Fisher Scientific Inc.
- Nom
- Thermo Fisher Scientific Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NYSE
- Capitalisation
- $247.7B
- Employés
- 125,000
- PDG
- Marc N. Casper
- Site web
- https://www.thermofisher.com
- Marché
- ABIOBMXXYBRKRDHRMTD
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 40 550 titres (~24 212 864,50 $ US)
- Insiders
- CASPER MARC N
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$20,348,284
Avg sell (VWAP, 90d window) $602.25 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,811,123 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-24
- Last synced
-
2026-08-30 10:16:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-31 | Pettiti Gianluca | Sell · S · 10b5-1 | 3,733 | $614.38 | $2,293,481 | Form 4 |
| 2026-08-24 | CASPER MARC N | Sell · S · 10b5-1 | 62 | $628.74 | $38,982 | Form 4 |
| 2026-08-21 | CASPER MARC N | Sell · S · 10b5-1 | 321 | $629.10 | $201,941 | Form 4 |
| 2026-08-20 | CASPER MARC N | Sell · S · 10b5-1 | 80 | $633.99 | $50,719 | Form 4 |
| 2026-08-19 | Britt Lisa P. | Sell · S | 11,440 | $613.12 | $7,014,093 | Form 4 |
| 2026-08-11 | Shafer Michael D | Sell · S | 11,200 | $600.00 | $6,720,000 | Form 4 |
| 2026-08-07 | CASPER MARC N | Sell · S | 117 | $593.31 | $69,417 | Form 4 |
| 2026-08-07 | Holmes Joseph R. | Sell · S | 420 | $584.81 | $245,620 | Form 4 |
| 2026-08-06 | Britt Lisa P. | Sell · S | 5,850 | $580.00 | $3,393,000 | Form 4 |
| 2026-08-06 | CASPER MARC N | Sell · S | 127 | $580.01 | $73,661 | Form 4 |
| 2026-08-05 | CASPER MARC N | Sell · S | 37 | $577.56 | $21,370 | Form 4 |
| 2026-07-27 | Pettiti Gianluca | Sell · S · 10b5-1 | 400 | $565.00 | $226,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-10 | Dan Newhouse | Sale | $1,001 - $15,000 |
| 2026-05-07 | Dwight Evans | Sale (Partial) | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-03-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-12 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $15,001 - $50,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $15,001 - $50,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $1,001 - $15,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $1,001 - $15,000 |
| 2025-08-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-25 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-10 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-06 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2025-05-16 | Richard W. Allen | Sale | $15,001 - $50,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-05-05 | Thomas H. Kean | Purchase | $1,001 - $15,000 |
| 2025-04-28 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale | $1,001 - $15,000 |
| 2025-04-11 | Dan Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-11 | Richard W. Allen | Sale | $15,001 - $50,000 |
| 2025-04-08 | Rob Bresnahan | Sale | $15,001 - $50,000 |
| 2025-03-27 | Greg Landsman | Sale | $1,001 - $15,000 |
| 2025-03-03 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2024-12-12 | Michael Rulli | Sale | $1,001 - $15,000 |
| 2024-12-11 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-10 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-03-06 | John James | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-09 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2024-02-09 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John Curtis | Sale | $1,001 - $15,000 |
| 2023-11-28 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-26 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $50,001 - $100,000 |
| 2023-06-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-28 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-21 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-06-21 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-05-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-19 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-05-02 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-05-02 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-02-23 | John Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-31 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2023-01-11 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-30 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-10-12 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-07-22 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-07-22 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-07-15 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-03-10 | Richard W. Allen | Purchase | $15,001 - $50,000 |
| 2022-03-08 | Dan Newhouse | Purchase | $1,001 - $15,000 |
| 2021-11-02 | Dan Newhouse | Purchase | $1,001 - $15,000 |
| 2021-04-12 | Richard W. Allen | Sale (Partial) | $15,001 - $50,000 |
| 2021-03-10 | Richard W. Allen | Purchase | $15,001 - $50,000 |
| 2021-01-25 | Richard W. Allen | Purchase | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-09-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
TMO presents solid liquidity (85) and decent fundamental health (65), but the weak catalyst score (25) driven by a significant $24.2M insider sale from the CEO heavily undermines near-term conviction.
The first sentence of the analysis written for TMO on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.89 · operating margin 18%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 37.7% | 41.3% | 40.1% | 42.3% | 50.1% | |
| Ebit Margin | 19.5% | 20.3% | 18.2% | 19.1% | 23.9% | |
| Ebitda Margin | 25.7% | 27.5% | 26.1% | 26.6% | 30.5% | |
| Operating Profit Margin | 18.2% | 17.9% | 17.4% | 19.0% | 26.3% | |
| Pretax Profit Margin | 16.3% | 16.3% | 14.6% | 17.1% | 22.5% | |
| Continuous Operations Profit Margin | 15.1% | 14.8% | 13.9% | 15.5% | 19.7% | |
| Net Profit Margin | 15.1% | 14.8% | 14.0% | 15.5% | 19.7% | |
| Bottom Line Profit Margin | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | |
| Current Ratio | 1.890 | 1.660 | 1.755 | 1.483 | 1.497 | |
| Quick Ratio | 1.533 | 1.287 | 1.392 | 1.152 | 1.121 | |
| Solvency Ratio | 0.168 | 0.198 | 0.181 | 0.195 | 0.191 | |
| Cash Ratio | 0.649 | 0.301 | 0.577 | 0.501 | 0.333 | |
| Price To Earnings Ratio | 32.608 | 31.377 | 34.178 | 31.060 | 34.025 | |
| Price To Earnings Growth Ratio | 4.543 | 4.641 | -2.754 | -3.240 | 1.561 | |
| Forward Price To Earnings Growth Ratio | 4.543 | 4.641 | -2.754 | -3.240 | 1.561 | |
| Price To Earnings Diluted Ratio | 32.663 | 31.472 | 34.355 | 31.218 | 34.288 | |
| Price To Earnings Diluted Growth Ratio | 4.462 | 4.502 | -2.767 | -3.338 | 1.574 | |
| Price To Book Ratio | 4.079 | 4.008 | 4.384 | 4.909 | 6.445 | |
| Price To Sales Ratio | 4.890 | 4.635 | 4.781 | 4.806 | 6.705 | |
| Price To Free Cash Flow Ratio | 34.622 | 27.347 | 29.578 | 31.236 | 37.449 | |
| Price To Operating Cash Flow Ratio | 27.868 | 22.929 | 24.374 | 23.582 | 27.548 | |
| Debt To Assets Ratio | 0.357 | 0.337 | 0.369 | 0.371 | 0.382 | |
| Debt To Equity Ratio | 0.737 | 0.661 | 0.779 | 0.820 | 0.891 | |
| Debt To Capital Ratio | 0.424 | 0.398 | 0.438 | 0.451 | 0.471 | |
| Long Term Debt To Capital Ratio | 0.402 | 0.370 | 0.401 | 0.397 | 0.441 | |
| Financial Leverage Ratio | 2.066 | 1.963 | 2.112 | 2.209 | 2.332 | |
| Working Capital Turnover Ratio | 3.992 | 4.425 | 4.560 | 6.030 | 4.278 | |
| Operating Cash Flow Ratio | 0.515 | 0.650 | 0.600 | 0.538 | 0.710 | |
| Operating Cash Flow Sales Ratio | 0.175 | 0.202 | 0.196 | 0.204 | 0.243 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.805 | 0.838 | 0.824 | 0.755 | 0.736 | |
| Debt Service Coverage Ratio | 2.205 | 2.699 | 2.034 | 1.709 | 3.252 | |
| Interest Coverage Ratio | 5.715 | 4.632 | 4.994 | 11.742 | 19.250 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.213 | 3.502 | 2.171 | 1.565 | 3.405 | |
| Operating Cash Flow Coverage Ratio | 0.199 | 0.264 | 0.231 | 0.254 | 0.263 | |
| Capital Expenditure Coverage Ratio | 5.127 | 6.191 | 5.684 | 4.081 | 3.782 | |
| Dividend Paid And Capex Coverage Ratio | 3.618 | 4.371 | 4.199 | 3.393 | 3.270 | |
| Dividend Payout Ratio | 0.094 | 0.092 | 0.087 | 0.065 | 0.051 | |
| Enterprise Value Multiple | 21.577 | 19.278 | 20.833 | 20.383 | 24.626 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 37.7% | ▼-3.7% | ▼-4.7% |
| Ebit Margin | 19.5% | ▼-0.8% | ▼-0.7% |
| Ebitda Margin | 25.7% | ▼-1.8% | ▼-1.6% |
| Operating Profit Margin | 18.2% | ▲0.3% | ▼-1.6% |
| Pretax Profit Margin | 16.3% | -0.0% | ▼-1.1% |
| Continuous Operations Profit Margin | 15.1% | ▲0.3% | ▼-0.7% |
| Net Profit Margin | 15.1% | ▲0.4% | ▼-0.7% |
| Bottom Line Profit Margin | 15.0% | ▲0.3% | ▼-0.8% |
| Current Ratio | 1.890 | ▲0.230 | ▲0.233 |
| Quick Ratio | 1.533 | ▲0.246 | ▲0.236 |
| Solvency Ratio | 0.168 | ▼-0.031 | ▼-0.019 |
| Cash Ratio | 0.649 | ▲0.347 | ▲0.176 |
| Price To Earnings Ratio | 32.608 | ▲1.231 | ▼-0.042 |
| Price To Earnings Growth Ratio | 4.543 | ▼-0.098 | ▲3.593 |
| Forward Price To Earnings Growth Ratio | 4.543 | ▼-0.098 | ▲3.593 |
| Price To Earnings Diluted Ratio | 32.663 | ▲1.192 | ▼-0.136 |
| Price To Earnings Diluted Growth Ratio | 4.462 | ▼-0.040 | ▲3.575 |
| Price To Book Ratio | 4.080 | ▲0.072 | ▼-0.685 |
| Price To Sales Ratio | 4.890 | ▲0.255 | ▼-0.273 |
| Price To Free Cash Flow Ratio | 34.621 | ▲7.275 | ▲2.575 |
| Price To Operating Cash Flow Ratio | 27.868 | ▲4.939 | ▲2.608 |
| Debt To Assets Ratio | 0.357 | ▲0.020 | ▼-0.006 |
| Debt To Equity Ratio | 0.738 | ▲0.076 | ▼-0.040 |
| Debt To Capital Ratio | 0.424 | ▲0.026 | ▼-0.012 |
| Long Term Debt To Capital Ratio | 0.402 | ▲0.032 | ▼-0.000 |
| Financial Leverage Ratio | 2.066 | ▲0.103 | ▼-0.070 |
| Working Capital Turnover Ratio | 3.992 | ▼-0.433 | ▼-0.665 |
| Operating Cash Flow Ratio | 0.515 | ▼-0.135 | ▼-0.088 |
| Operating Cash Flow Sales Ratio | 0.175 | ▼-0.027 | ▼-0.029 |
| Free Cash Flow Operating Cash Flow Ratio | 0.805 | ▼-0.034 | ▲0.013 |
| Debt Service Coverage Ratio | 2.205 | ▼-0.494 | ▼-0.175 |
| Interest Coverage Ratio | 5.715 | ▲1.082 | ▼-3.552 |
| Short Term Operating Cash Flow Coverage Ratio | 2.213 | ▼-1.289 | ▼-0.358 |
| Operating Cash Flow Coverage Ratio | 0.199 | ▼-0.066 | ▼-0.043 |
| Capital Expenditure Coverage Ratio | 5.127 | ▼-1.064 | ▲0.154 |
| Dividend Paid And Capex Coverage Ratio | 3.618 | ▼-0.753 | ▼-0.152 |
| Dividend Payout Ratio | 0.094 | ▲0.002 | ▲0.016 |
| Enterprise Value Multiple | 21.577 | ▲2.299 | ▲0.238 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $217.87B | $198.73B | $204.88B | $215.87B | $262.89B | |
| Enterprise value | $247.41B | $227.48B | $233.23B | $243.42B | $294.75B | |
| EV / Sales | 5.55x | 5.30x | 5.44x | 5.42x | 7.52x | |
| EV / Op. cash flow | 31.65x | 26.25x | 27.75x | 26.59x | 30.89x | |
| EV / Free cash flow | 39.31x | 31.30x | 33.67x | 35.22x | 41.99x | |
| EV / EBITDA | 21.58x | 19.28x | 20.83x | 20.38x | 24.63x | |
| Net debt / EBITDA | 2.58x | 2.44x | 2.53x | 2.31x | 2.66x | |
| Current ratio | 1.89x | 1.66x | 1.75x | 1.48x | 1.50x | |
| Income quality | 1.16x | 1.37x | 1.40x | 1.31x | 1.24x | |
| Graham number | $239 | $220 | $206 | $212 | $214 | |
| Graham net-net | -$96 | -$85 | -$88 | -$88 | -$103 | |
| Tax burden | 92.7% | 90.6% | 96.1% | 90.7% | 87.4% | |
| Interest burden | 83.7% | 80.5% | 80.1% | 89.5% | 94.2% | |
| Working capital | $13.52B | $8.80B | $10.58B | $8.22B | $6.68B | |
| Invested capital | $89.28B | $80.99B | $82.27B | $77.77B | $78.61B | |
| Return on assets | 6.1% | 6.5% | 6.1% | 7.2% | 8.1% | |
| Operating ROA | 7.8% | 7.8% | 7.6% | 8.9% | 12.6% | |
| Return on tangible assets | 14.9% | 17.6% | 15.8% | 18.1% | 23.4% | |
| Return on equity | 12.6% | 12.8% | 12.8% | 15.8% | 18.9% | |
| Return on invested capital | 7.6% | 8.0% | 8.0% | 9.0% | 10.7% | |
| Return on capital employed | 8.5% | 9.1% | 8.8% | 10.6% | 12.6% | |
| Earnings yield | 3.1% | 3.2% | 2.9% | 3.2% | 2.9% | |
| Free cash flow yield | 2.9% | 3.7% | 3.4% | 3.2% | 2.7% | |
| Capex / Op. cash flow | 19.5% | 16.2% | 17.6% | 24.5% | 26.4% | |
| Capex / Depreciation | 54.9% | 45.0% | 43.4% | 66.3% | 97.3% | |
| Capex / Sales | 3.4% | 3.3% | 3.5% | 5.0% | 6.4% | |
| SG&A / Sales | 16.3% | 20.2% | 19.6% | 20.1% | 20.2% | |
| R&D / Sales | 3.1% | 3.2% | 3.1% | 3.3% | 3.6% | |
| Stock comp / Sales | 0.7% | 0.7% | 0.6% | 0.7% | 0.6% | |
| Intangibles / Total assets | 59.1% | 63.1% | 61.5% | 60.4% | 65.3% | |
| Days sales outstanding | 87d | 82d | 82d | 77d | 83d | |
| Days payables outstanding | 48d | 45d | 41d | 48d | 53d | |
| Operating cycle | 158d | 154d | 155d | 156d | 177d | |
| Cash conversion cycle | 110d | 109d | 114d | 108d | 124d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-29 37,709 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Beacon Pointe Advisors LLC Beacon Pointe Advisors LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 37,709 shares of the medical research company''s stock, valued at approximately $18,906,000. Several other hedge funds also recently modified their holdings of
- 2026-08-28 Ausdal Financial Partners Inc. Makes New $456,000 Investment in Thermo Fisher Scientific Inc. $TMO Ausdal Financial Partners Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 910 shares of the medical research company''s stock, valued at approximately $456,000. Several other hedge funds and other
- 2026-08-28 Bank OZK Takes $1.10 Million Position in Thermo Fisher Scientific Inc. $TMO Bank OZK purchased a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,186 shares of the medical research company''s stock, valued at approximately $1,096,000. A number of other
- 2026-08-27 Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better.
- 2026-08-26 Delta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC''s ‘Final Trades'' On CNBC''s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Delta Air Lines, Inc. (NYSE:DAL).
- 2026-08-25 Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company''s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analys.
- 2026-08-24 Is TMO Overvalued? DCF Says Worth $491 On August 24, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO) amidst a backdrop of strong price performance, with the stock up 30.6% ov
- 2026-08-22 Avanda Investment Management Pte. Ltd. Invests $2 Million in Thermo Fisher Scientific Inc. $TMO Avanda Investment Management Pte. Ltd. acquired a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,000 shares of the medical research company''s stock, valued at approximately $2,005,000. Thermo Fisher Scientific accounts for
- 2026-08-22 Allworth Financial LP Takes $12.20 Million Position in Thermo Fisher Scientific Inc. $TMO Allworth Financial LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,334 shares of the medical research company''s stock, valued at approximately $12,200,000. Several other hedge funds
- 2026-08-21 Bank of New York Mellon Corp Invests $1.97 Billion in Thermo Fisher Scientific Inc. $TMO Bank of New York Mellon Corp bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,938,410 shares of the medical research company''s stock, valued at approximately $1,974,561,000. Bank of New